Valeant Pharma (VRX) Corrects adj.-EBITDA Guidance Lower to ~$6B on Call
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Deutsche Bank Comments on Valeant Pharma (VRX) Following Q4 Call
March 15, 2016 2:20 PM EDTDeutsche Bank analyst Gregg Gilbert commented on Valeant Pharma (NYSE: VRX) after it released Q4 earnings and discussed challenges on its conference call. The analyst noted operational challenges and overhang from its 10-K delay.
"The new 2016 guidance reflects in large part lower growth assumptions for the core US business (including Dermatology and GI) without offsetting cost reductions (which the company will explore). On the positive side, VRX described making progress with payors, and cited greater visibility on managed... More
UPDATE: Piper Jaffray Downgrades Valeant Pharmaceuticals (VRX) to Underweight
March 15, 2016 11:15 AM EDT(Updated - March 15, 2016 11:20 AM EDT)
Piper Jaffray downgraded Valeant Pharmaceuticals (NYSE: VRX) from Neutral to Underweight. Analyst David Amsellem called Valeant a "broken company" and noted trouble spots across a number of segments.
Amsellem explained the downgrade, "VRX reported 4Q15 adjusted... More
Valeant Pharma (VRX) Results Suggest Disruption in the Business - Evecore ISI's Raffat
March 15, 2016 10:56 AM EDTEvercore ISI analyst, Umer Raffat, commented on Valeant Pharma (NYSE: VRX) after the call.
"I think it will be an understatement to say that this has clearly been a very humbling call for me," he said.
".. today's results suggests that while... More
Valeant Pharma (VRX) Conference Call Ends
March 15, 2016 10:13 AM EDTValeant Pharma (NYSE: VRX) brutal conference call ends. With shares down 36.7% traders will be looking for the stock to possibly rally later in the session.
... MoreValeant Pharma (VRX) Misses Q4 EPS by 11c; Cuts Q1, FY16 Outlook
March 15, 2016 6:03 AM EDTValeant Pharma (NYSE: VRX) reported Q4 EPS of $2.50, $0.11 worse than the analyst estimate of $2.61. Revenue for the quarter came in at $2.8 billion versus the consensus estimate of $2.75 billion.
GUIDANCE:
Valeant Pharma sees Q1 2016 EPS of $1.30 - $1.55, versus prior guidance of $2.35 - $2.55 and the consensus of $2.63. Valeant Pharma sees Q1 2016 revenue of $2.3 - $2.4 billion, versus prior guidance of $2.8 - $3.1 billion and the consensus of $2.82 billion.
Valeant Pharma sees FY2016 EPS... More
